Literature DB >> 1359802

Immunity to Hantavirus challenge in Meriones unguiculatus induced by vaccinia-vectored viral proteins.

X Xu1, S L Ruo, J B McCormick, S P Fisher-Hoch.   

Abstract

Vaccinia virus recombinants were constructed that incorporated genomic sequences coding for the nucleoprotein (N) and glycoproteins (G1 and G2) of the hantavirus R22 strain isolated from a rat in China, and designated as RNV and RMV9, respectively. The proteins expressed by RNV and RMV9 were identified by radioimmunoprecipitation and indirect immunofluorescence assay using a panel of monoclonal antibodies and polyclonal immune sera, and were found to be antigenically indistinguishable from authentic R22 viral proteins. Both RNV and RMV9 elicited an anti-R22 antibody response in Mongolian gerbils (Meriones unguiculatus) with titers ranging from 6,400 to 12,800 by enzyme-linked immunosorbent assay, but only RMV9 produced neutralizing antibodies to R22 virus (titer 1:200) and Hantaan (HTN) virus (titer 1:20). The ability of these recombinants to protect Mongolian gerbils against challenge with R22 and HTN viruses was examined. The RMV9 recombinant induced a complete protective immune response against challenge with 10(4) plaque-forming units (PFU) of both R22 and HTN viruses, while RNV induced partial protection against a challenge with the homologous R22 virus and the heterologous HTN virus at a dose of 10(3) PFU. Our data show that the common antigenic sites responsible for eliciting a protective response are located mainly on hantavirus glycoproteins, and that the nucleoprotein may also confer partial cross-protection that presumably involves cell-mediated as well as humoral mechanisms.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1359802     DOI: 10.4269/ajtmh.1992.47.397

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  11 in total

Review 1.  The Syrian hamster model of hantavirus pulmonary syndrome.

Authors:  David Safronetz; Hideki Ebihara; Heinz Feldmann; Jay W Hooper
Journal:  Antiviral Res       Date:  2012-06-15       Impact factor: 5.970

Review 2.  Treatment of hantavirus pulmonary syndrome.

Authors:  Colleen B Jonsson; Jay Hooper; Gregory Mertz
Journal:  Antiviral Res       Date:  2007-11-21       Impact factor: 5.970

3.  Protection from La Crosse virus encephalitis with recombinant glycoproteins: role of neutralizing anti-G1 antibodies.

Authors:  A Pekosz; C Griot; K Stillmock; N Nathanson; F Gonzalez-Scarano
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

4.  DNA vaccination with the Hantaan virus M gene protects Hamsters against three of four HFRS hantaviruses and elicits a high-titer neutralizing antibody response in Rhesus monkeys.

Authors:  J W Hooper; D M Custer; E Thompson; C S Schmaljohn
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

Review 5.  Human pathogenic hantaviruses and prevention of infection.

Authors:  Detlev H Krüger; Günther Schönrich; Boris Klempa
Journal:  Hum Vaccin       Date:  2011-06-01

6.  Adenovirus vectors expressing hantavirus proteins protect hamsters against lethal challenge with andes virus.

Authors:  David Safronetz; Nagendra R Hegde; Hideki Ebihara; Michael Denton; Gary P Kobinger; Stephen St Jeor; Heinz Feldmann; David C Johnson
Journal:  J Virol       Date:  2009-04-29       Impact factor: 5.103

7.  Cross-protection against challenge with Puumala virus after immunization with nucleocapsid proteins from different hantaviruses.

Authors:  Cristina de Carvalho Nicacio; Marcelo Gonzalez Della Valle; Paula Padula; Ewa Björling; Alexander Plyusnin; Ake Lundkvist
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

8.  Characterization of human antibody responses to four corners hantavirus infections among patients with hantavirus pulmonary syndrome.

Authors:  S Jenison; T Yamada; C Morris; B Anderson; N Torrez-Martinez; N Keller; B Hjelle
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

9.  Hantavirus Pulmonary Syndrome in the United States.

Authors:  Marilyn Fabbri; Melanie J. Maslow
Journal:  Curr Infect Dis Rep       Date:  2001-06       Impact factor: 3.725

10.  A Crimean-Congo hemorrhagic fever (CCHF) viral vaccine expressing nucleoprotein is immunogenic but fails to confer protection against lethal disease.

Authors:  S D Dowall; K R Buttigieg; S J D Findlay-Wilson; E Rayner; G Pearson; A Miloszewska; V A Graham; M W Carroll; R Hewson
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.